Your browser is no longer supported. Please, upgrade your browser.
Settings
IFRX InflaRx N.V. daily Stock Chart
IFRX [NASD]
InflaRx N.V.
Index- P/E- EPS (ttm)-1.31 Insider Own- Shs Outstand27.14M Perf Week-8.22%
Market Cap1.04B Forward P/E- EPS next Y-3.55 Insider Trans- Shs Float15.88M Perf Month-24.03%
Income-33.30M PEG- EPS next Q-0.57 Inst Own62.00% Short Float- Perf Quarter16.46%
Sales- P/S- EPS this Y-16.70% Inst Trans8.37% Short Ratio- Perf Half Y28.12%
Book/sh6.51 P/B5.90 EPS next Y- ROA-19.70% Target Price- Perf Year11.69%
Cash/sh2.28 P/C16.84 EPS next 5Y- ROE-20.40% 52W Range20.31 - 53.10 Perf YTD5.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.66% Beta-
Dividend %- Quick Ratio20.40 Sales past 5Y- Gross Margin- 52W Low89.12% ATR2.43
Employees38 Current Ratio20.40 Sales Q/Q- Oper. Margin- RSI (14)26.54 Volatility4.77% 5.60%
OptionableNo Debt/Eq0.00 EPS Q/Q15.40% Profit Margin- Rel Volume0.78 Prev Close39.85
ShortableYes LT Debt/Eq0.00 EarningsMay 16 Payout- Avg Volume224.88K Price38.41
Recom- SMA20-14.85% SMA50-14.21% SMA2008.21% Volume175,687 Change-3.61%
Jan-29-19Initiated Robert W. Baird Outperform
Dec-10-18Initiated Credit Suisse Outperform
Jul-13-18Initiated BMO Capital Markets Outperform $45
Jun-28-18Initiated SunTrust Buy $55
Jun-28-18Initiated Raymond James Outperform
Feb-08-18Initiated B. Riley FBR, Inc. Buy $40
May-14-19 08:00AM  InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe GlobeNewswire
May-03-19 10:12AM  Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX)? Insider Monkey
Apr-10-19 08:45AM  InflaRx (IFRX) Catches Eye: Stock Jumps 7.5% Zacks +7.38%
Mar-28-19 08:30AM  InflaRx Full Year 2018 Financial & Operating Results GlobeNewswire
Mar-12-19 07:37AM  InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year Simply Wall St.
Feb-27-19 08:30AM  InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum GlobeNewswire +5.81%
Feb-25-19 07:30AM  Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-14-19 08:30AM  Richard Brudnick to Join InflaRx Board of Directors GlobeNewswire
Feb-06-19 07:00AM  InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire
Jan-03-19 08:30AM  InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management GlobeNewswire
Dec-22-18 03:43AM  Is InflaRx N.V. (IFRX) A Good Stock To Buy? Insider Monkey
Dec-19-18 08:30AM  InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Nov-21-18 08:30AM  InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results GlobeNewswire +7.23%
Nov-08-18 02:30AM  InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire +8.06%
Oct-30-18 07:30AM  InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing GlobeNewswire
Oct-23-18 09:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V New Research Emphasizes Economic Growth GlobeNewswire
Sep-21-18 08:30AM  InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors GlobeNewswire
Aug-28-18 07:30AM  InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 GlobeNewswire +5.02%
Aug-09-18 07:00AM  InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results GlobeNewswire
Jun-28-18 07:30AM  InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Jun-05-18 07:30AM  InflaRx Opens New Research Facility in Ann Arbor GlobeNewswire
May-17-18 07:30AM  InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results GlobeNewswire
May-08-18 10:42AM  InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares GlobeNewswire
May-03-18 08:28PM  InflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares GlobeNewswire -7.05%
May-02-18 07:44AM  InflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares GlobeNewswire -6.54%
Mar-29-18 07:00AM  InflaRx Full Year 2017 Financial & Operating Results GlobeNewswire
Mar-12-18 08:40AM  Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa ACCESSWIRE +7.98%
Mar-08-18 08:23AM  InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Feb-06-18 07:52AM  InflaRx Announces Appointment of Tony Gibney to Its Board of Directors Business Wire
Feb-01-18 09:55AM  InflaRx Presents at Two Scientific Conferences in February, 2018 Business Wire
Jan-23-18 01:53PM  Breaking Down InflaRx NVs (NASDAQ:IFRX) Ownership Structure Simply Wall St.
Jan-15-18 10:51AM  What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward? Simply Wall St.
Jan-09-18 08:56AM  InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Jan-04-18 01:47PM  InflaRx to Present at Upcoming Investor Conferences Business Wire +13.56%
08:00AM  InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear? Simply Wall St.
Nov-10-17 08:05AM  The Biotech IPO Boom Will Continue, Nasdaq Execs Predict Forbes
Nov-08-17 01:31PM  InflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.